EGFR-TKI resistance and epigenetic alterations in lung cancer treatment

2016 Fiscal Year Final Research Report

• Project/Area Number: 16H06988
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Respiratory surgery
• Research Institution: Okayama University
• Principal Investigator: Shien Kazuhiko 岡山大学, 大学病院, 助教 (30708079)
• Research Collaborator: SATO Hiroki ; TOMIDA Shuta ; TOYOOKA Shinichi
• Project Period (FY): 2016-08-26 – 2017-03-31
• Keywords: 非小細胞肺癌 / EGFR / 薬剤耐性 / マイクロRNA

Outline of Final Research Achievements

Patients with EGFR-activating mutations who initially respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually acquire drug resistance, which is a critical problem in the treatment of patients with advanced lung cancer. In this study, we clarified the relation between epigenetic alteration and EGFR-TKI resistance. We found that the micro RNA-200 and LIN28B axis, known as an oncogenic stem-cell factor, plays an important role in the cell viability of acquired EGFR-TKI resistance cells.

Free Research Field

胸部悪性腫瘍（肺癌・悪性胸膜中皮腫）おける治療感受性・抵抗性に関する研究、肺癌の外科治療